Review questions intermittent fasting for weight loss

A new review of studies suggests that intermittent fasting offers no significant advantage over traditional dieting or no intervention for weight loss among overweight or obese adults. Researchers analyzed data from 22 trials involving nearly 2,000 participants. While the approach remains popular, experts highlight limitations in the evidence.

Intermittent fasting, a dieting method that alternates between eating and fasting periods, has gained popularity as a strategy for shedding excess weight. Common forms include the 16:8 approach, where individuals fast for 16 hours and eat within an eight-hour window, and the 5:2 method, which involves normal eating five days a week and severe calorie restriction on the other two. The core premise is that time-restricted eating naturally lowers overall calorie consumption.

However, a systematic review published in the Cochrane Database of Systematic Reviews challenges its effectiveness. Led by Luis Garegnani at the Italian Hospital of Buenos Aires in Argentina, the analysis examined 22 randomized controlled trials with almost 2,000 adults aged 18 to 80 from regions including North America, Europe, China, Australia, and South America. All participants were overweight or had obesity.

The findings indicate no meaningful difference in weight loss when comparing intermittent fasting to standard dietary guidance. Against a control group making no changes, the diet also showed no superior results. "Intermittent fasting just doesn’t seem to work for overweight or obese adults trying to lose weight," Garegnani stated in a press release.

Challenges in the data include inconsistencies across studies, complicating definitive conclusions. Even when results were stratified by gender or fasting type, benefits remained elusive. Satchidananda Panda at the Salk Institute for Biological Studies in California critiqued the review, pointing out that most trials failed to verify participant adherence. "If we don’t know whether participants actually followed the intervention, what, exactly, are we systematically reviewing?" he remarked. "It’s a bit like building a cathedral on quicksand and then performing a meta-analysis of the architecture."

The review concentrated solely on weight loss outcomes, leaving other potential health impacts—such as effects on heart disease risk, immunity, gut function, or liver health—unaddressed, as prior research offers mixed signals. Garegnani emphasized that while intermittent fasting might suit some people, it is no panacea. "Intermittent fasting is not a miracle solution," he said. "[It] may be a useful option for some individuals, but it shouldn’t distract from broader, population-level strategies to prevent and manage obesity."

Relaterede artikler

Illustration of a study participant with brain scans and gut bacteria visuals related to intermittent fasting research.
Billede genereret af AI

Intermittent energy restriction tied to shifts in brain activity and gut microbiome, small study suggests

Rapporteret af AI Billede genereret af AI Faktatjekket

A small 2023 study of adults with obesity in China found that an intermittent energy restriction program was associated with weight loss and changes in gut bacteria alongside altered activity in brain regions linked to appetite, cravings and self-control.

A seven-day water-only fast triggers major molecular shifts across the body, with the most significant effects emerging only after three days without food. Researchers tracked protein changes in healthy volunteers to map these responses in detail. The findings highlight both potential health benefits and risks of prolonged fasting.

Rapporteret af AI Faktatjekket

A Stanford Medicine-led randomized trial in the United States found that a five-day-per-month fasting-mimicking diet was linked to improved patient-reported symptoms and lower biological markers of inflammation in adults with mild-to-moderate Crohn’s disease. The results were published in Nature Medicine.

An international meta-analysis slated for presentation at the European Congress on Obesity (ECO 2026) in Istanbul, Turkey (May 12–15) suggests that people who increase their walking to roughly 8,500 steps a day during a weight-loss program and sustain similar levels afterward may be less likely to regain weight.

Rapporteret af AI Faktatjekket

A randomized, placebo-controlled trial led by Australia’s Garvan Institute of Medical Research found that metformin, a long-used and low-cost drug for type 2 diabetes, did not improve clamp-measured insulin resistance in adults with type 1 diabetes but was associated with roughly 12% lower insulin requirements while blood sugar measures remained broadly unchanged.

Dette websted bruger cookies

Vi bruger cookies til analyse for at forbedre vores side. Læs vores privatlivspolitik for mere information.
Afvis